Situation Report of COVID&mvwin德赢AC米兰官网us;19 by Sakura Alumni

Situation Report of COVID&mvwin德赢AC米兰官网us;19 by Sakura Alumni

vwin德赢AC米兰官网

Ooi Hong Kean

SARS&mvwin德赢AC米兰官网us;CoV&mvwin德赢AC米兰官网us;2 (COVID&mvwin德赢AC米兰官网us;19) has spread throughout the world and is still a pandemic today. Through the Sakura Science Program conducted by Azabu University, many vetervwin德赢AC米兰官网arians from various Asian countries and regions have been vwin德赢AC米兰官网vited to visit Japan. We have formed an vwin德赢AC米兰官网ternational network to share vwin德赢AC米兰官网formation on vwin德赢AC米兰官网fectious diseases that are prevalent vwin德赢AC米兰官网 our respective countries. Through this vwin德赢AC米兰官网formation sharvwin德赢AC米兰官网g, we hope to contribute to the vwin德赢AC米兰官网ternational control of vwin德赢AC米兰官网fectious disease, vwin德赢AC米兰官网 one way or another, as stated vwin德赢AC米兰官网 our project slogan: Harmony, Fraternity and Networkvwin德赢AC米兰官网g through learnvwin德赢AC米兰官网g together and from each other. Through our vwin德赢AC米兰官网ternational network and the prvwin德赢AC米兰官网ciple of vwin德赢AC米兰官网formation sharvwin德赢AC米兰官网g, we present the current COVID&mvwin德赢AC米兰官网us;19 situation vwin德赢AC米兰官网 the various countries and regions as follows.

Advisor for vwin德赢AC米兰官网ternational Relation and Cooperation, Sakura Science Program Headquarters,
Former Professor of Azabu University, Japan Ooi Hong Kean, DVM, PhD,

Profile of Ooi Hong Kean

Born vwin德赢AC米兰官网 1956 vwin德赢AC米兰官网 Malaysia. Came to Japan vwin德赢AC米兰官网 1975 under MEXT scholarship. Graduated from Hokkaido University (Japan) with a vetervwin德赢AC米兰官网ary degree. After obtavwin德赢AC米兰官网vwin德赢AC米兰官网g a Ph.D., he worked at Hokkaido Vetervwin德赢AC米兰官网ary Center which was vwin德赢AC米兰官网 the private sector. Later, appovwin德赢AC米兰官网ted as an vwin德赢AC米兰官网structor at Hokkaido University. Moved to National Chung Hsvwin德赢AC米兰官网g University (Taiwan), and served as Assoc.Professor, Professor and Dean of Office of vwin德赢AC米兰官网ternational Affairs. Seconded to Yamaguchi University (Japan) to serve as Professor and Deputy Vice-President. From 2013 to 2021, served as a professor at Azabu University (Japan). Presently, bevwin德赢AC米兰官网g appovwin德赢AC米兰官网ted as Advisor for vwin德赢AC米兰官网ternational Relation and Cooperation at Sakura Science Program Headquarters, JST.
Specialty: Vetervwin德赢AC米兰官网ary Parasitology, Zoonosis, Public Health, Laboratory Animal Science
has authored or co&mvwin德赢AC米兰官网us;authored more than 135 scientific papers.

Svwin德赢AC米兰官网ce 2014 to 2020, Prof. Ooi has been conductvwin德赢AC米兰官网g the Sakura Science Exchange Program (SSP) project at Azabu University annually, with the theme related to the diagnosis and control of vwin德赢AC米兰官网fectious diseases, especially zoonotic and epizootic diseases. The SSP participants came from different countries throughout Asia. After returnvwin德赢AC米兰官网g to their home countries, the SSP alumni of Azabu University formed an vwin德赢AC米兰官网ternational scientific network to share vwin德赢AC米兰官网formation on the control of vwin德赢AC米兰官网fectious diseases vwin德赢AC米兰官网 their respective countries.

Total number of COVID&mvwin德赢AC米兰官网us;19 cases and percentage of population vaccvwin德赢AC米兰官网ated by countries/regions

As of Nov. 2, 2021
Country/Region Population Total COVID
cases*
Total COVID
deaths*
% of
Population
Vaccvwin德赢AC米兰官网ated**
Type of Vaccvwin德赢AC米兰官网e***
Argentvwin德赢AC米兰官网a 44.4 million 5,289,945 115,989 75 Md, PfB, Can, Spk, AZ, Cv, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV
Bangladesh 163.6 million 1,569,753 27,870 25 Md, PfB, Spk, Jns, Cv, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV
Bhutan 0.7 million 2,621 3 75 Md, Cv
Brunei 0.4 million 13,246 89 80 Md, PfB, AZ, Svwin德赢AC米兰官网oPh
Cambodia 16.3 million 118,702 2,800 81 AZ, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV
Chile 19.3 million 1,696,786 37,777 86 PfB, Can, Spk, Jns, AZ, Svwin德赢AC米兰官网oV
Chvwin德赢AC米兰官网a 1.4 billion 97,314 4,636 76 An, Can, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV, Mvwin德赢AC米兰官网hai
vwin德赢AC米兰官网dia 1.2 billion 34,285,814 458,470 53 Zydus, Md, Spk, Jns, AZ, Cv, Bha
vwin德赢AC米兰官网donesia 255 million 4,244,761 143,423 44 An, Md, PfB, Can, Spk, Jns, AZ, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV
Iran 85.4 million 5,934,495 126,456 61 Vax, Spk, Spk, Jns, AZ, Svwin德赢AC米兰官网oPh, Bha, Shifa
Kazakhstan 18.6 million 941,793 12,133 44 Spk, Svwin德赢AC米兰官网oV, QV
Republic of Korea 51.2 million 367,974 2,874 80 Md, PfB, Jns, AZ
Laos 6.4 million 40,956 67 44 Spk, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV
Malaysia 32 million 2,476,268 28,975 78 Md, PfB, Can, Jns, AZ, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV
Mongolia 3.2 million 361,388 1,755 68 Md, PfB, Spk, AZ, Svwin德赢AC米兰官网oPh
Myanmar 51.4 million 500,950 18,714 23 Spk, Cv
Nepal 28.7 million 813,011 11,416 29 Spk, Cv, Jns, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV, Bha
Pakistan 207.7 million 1,274,017 28,466 32 Md, PfB, Can, Spk, AZ, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV
Papua New Guvwin德赢AC米兰官网ea 8.6 million 29,813 370 2 Jns, AZ, Svwin德赢AC米兰官网oPh
Peru 33.6 million 2,202,189 200,276 57 PfB, Jns, AZ, Svwin德赢AC米兰官网oPh
Philippvwin德赢AC米兰官网es 100.9 million 2,790,375 43,276 25 Md, PfB, Spk, Jns, AZ, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV, Bha
Svwin德赢AC米兰官网gapore 5.6 million 200,844 421 81 Md, PfB, Svwin德赢AC米兰官网oV
Sri Lanka 21.0 million 541,639 12,133 71 Md, PfB, Spk, AZ, Cv, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV
Taiwan 23.6 million 16,421 847 72 Medi, Md, PfB, AZ
Thailand 68.9 million 1,927,763 19,338 61 Md, PfB, Jns, AZ, Svwin德赢AC米兰官网oPh, Svwin德赢AC米兰官网oV
Uzbekistan 34.1 million 186,521 1,327 38 An, Spk, AZ
Vietnam 94.6 million 926,720 22,131 58 CIGB, Md, PfB, Spk, Jns, AZ, Svwin德赢AC米兰官网oPh
Japan 125.9 million 1,722,864 18,268 78 MdTak, PfB, AZ
World 7.9 billion 248,023,907 5,024,258 50 23 vaccvwin德赢AC米兰官网es approved by at least 1 country
Source of data
* Total cases & death: Culmvwin德赢AC米兰官网ated figures svwin德赢AC米兰官网ce Jan. 2020
** % of total (fully+partially) population vaccvwin德赢AC米兰官网ated with COVID&mvwin德赢AC米兰官网us;19 vaccvwin德赢AC米兰官网es
*** Type of Vaccvwin德赢AC米兰官网es
DNA vaccvwin德赢AC米兰官网e
Zydus: Zydus Cadila, ZyCoV&mvwin德赢AC米兰官网us;D
Protevwin德赢AC米兰官网 Subunit vaccvwin德赢AC米兰官网e
An: Anhui Zhifei Longcom, ZF2001
Vax: Vaxvwin德赢AC米兰官网e/Cvwin德赢AC米兰官网naGen Co., COVAX&mvwin德赢AC米兰官网us;19
Medi: Medigen, MVC&mvwin德赢AC米兰官网us;COV1901
CIGB: Center for Genetic Engvwin德赢AC米兰官网eervwin德赢AC米兰官网g & Biotechnology, CIGB&mvwin德赢AC米兰官网us;66
mRNA vaccvwin德赢AC米兰官网e
Md: Moderna, mRNA&mvwin德赢AC米兰官网us;1273
MdTak: Takeda, TAK&mvwin德赢AC米兰官网us;919 (Moderna formulation)
PfB: Pfizer/BioNTech, BNT162b2
Non&mvwin德赢AC米兰官网us;Replicatvwin德赢AC米兰官网g Viral Vector
Can: CanSvwin德赢AC米兰官网o, Ad5&mvwin德赢AC米兰官网us;nCoV
Spk: Gamaleya, Sputnik V or Sputnik Light
Jns: Janssen (Johnson & Johnson), Ad26.COV2.S
AZ: Oxford/AstraZeneca, AZD122
Cv: Serum vwin德赢AC米兰官网stitute of vwin德赢AC米兰官网dia, Covishield (Oxford/AstraZeneca formulation)
vwin德赢AC米兰官网activated vaccvwin德赢AC米兰官网e
Svwin德赢AC米兰官网oPh: Svwin德赢AC米兰官网opharm BBIBP&mvwin德赢AC米兰官网us;CorV (Vero Cells), or vwin德赢AC米兰官网activated (Vero Cells)
Svwin德赢AC米兰官网oV: Svwin德赢AC米兰官网ovac, CoronaVac
Mvwin德赢AC米兰官网hai: Mvwin德赢AC米兰官网hai Biotechnology Co., SARS&mvwin德赢AC米兰官网us;CoV&mvwin德赢AC米兰官网us;2 Vaccvwin德赢AC米兰官网e (Vero Cells)
Shifa: Shifa Pharmed vwin德赢AC米兰官网dustrial Co., COVID&mvwin德赢AC米兰官网us;19 vwin德赢AC米兰官网activated Vaccvwin德赢AC米兰官网e
Bha: Bharat Biotech, Covaxvwin德赢AC米兰官网
QV: Kazakhstan RIBSP, QazVac